As of June 21, 2025, Matinas BioPharma Holdings Inc (MTNB) reports a EV/EBITDA of 0.10.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Matinas BioPharma Holdings Inc's EV/EBITDA to Peers
To better understand Matinas BioPharma Holdings Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Matinas BioPharma Holdings Inc (MTNB) | 0.10 |
| X4 Pharmaceuticals Inc (XFOR) | 2.62 |
| Aeterna Zentaris Inc (AEZS.TO) | 0.72 |
| Aptinyx Inc (APTX) | 0.15 |
| Marker Therapeutics Inc (MRKR) | -0.27 |
| Yumanity Therapeutics Inc (YMTX) | -0.39 |
Compared to its competitors, Matinas BioPharma Holdings Inc's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.